Home › Analyst: In Merck-Idenix deal, 'biggest question' is why Gilead wasn't the suitor
 

Keywords :   


Analyst: In Merck-Idenix deal, 'biggest question' is why Gilead wasn't the suitor

2014-06-18 21:04:16| Biotech - Topix.net

If Merck & Co .' s $4 billion bet on the hepatitis C drug being developed by Cambridge biotech firm Idenix Pharmaceuticals pays off, it will provide Merck with a slice of an estimated $50 billion market over the next decade.

Tags: the question deal biggest

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.09BIO completes transition of Thr Pro 80% to 85% Active
28.09This Week in Agribusiness, September 28, 2024
28.09This Week in Agribusiness, September 28, 2024
28.09Eastern North Pacific Tropical Weather Outlook
28.09Atlantic Tropical Weather Outlook
28.09Weekly Recap: AkzoNobel, BASF, Axalta, PPG Top This Weeks Stories
28.09Post-Tropical Cyclone Helene Graphics
28.09Post-Tropical Cyclone Helene Public Advisory Number 20
More »